Onderneming Regeneron Pharmaceuticals, Inc.
Aandelen
REGN
US75886F1075
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
894 USD | -0,80% | -2,86% | +1,79% |
17/04 | REGENERON PHARMACEUTICALS, INC. : UBS herhaalt koopadvies | ZM |
16/04 | Regeneron wil zich verdedigen tegen klacht DOJ over manipulatie geneesmiddelenprijs | RE |
Vakgebied
- inkomsten uit de verkoop van producten (56,6%);
- inkomsten uit samenwerkingsovereenkomsten (40,4%): samenwerking met Sanofi (58,1% van de inkomsten), Bayer (29,1%) en Roche (12,8%);
- overige (3%): voornamelijk inkomsten uit de verkoop van technologielicenties en uitbestede onderzoeksdiensten.
Eind 2022 had de groep een portefeuille van ongeveer 35 producten in klinische ontwikkeling.
Aantal werknemers: 13 450
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Medicines
100,0
%
| 12 173 | 100,0 % | 13 117 | 100,0 % | +7,76% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
51,5
%
| 6 821 | 56,0 % | 6 754 | 51,5 % | -0,98% |
Rest of World
44,4
%
| 4 987 | 41,0 % | 5 827 | 44,4 % | +16,85% |
Other
4,1
%
| 365 | 3,0 % | 536 | 4,1 % | +46,84% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 64 | 08-01-88 | |
Chief Executive Officer | 71 | 08-01-88 | |
Director of Finance/CFO | 54 | 01-01-03 | |
Melissa Lozner
CMP | Compliance Officer | - | 01-01-22 |
Bob McCowan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrew Murphy
CTO | Chief Tech/Sci/R&D Officer | 66 | 01-01-99 |
Neil Stahl
CTO | Chief Tech/Sci/R&D Officer | 67 | 01-01-91 |
Patrice Gilooly
COO | Chief Operating Officer | - | 01-01-98 |
Chief Tech/Sci/R&D Officer | - | 01-01-19 | |
Mark Hudson
IRO | Public Communications Contact | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 12-11-10 |
Chief Executive Officer | 71 | 08-01-88 | |
Michael Brown
BRD | Director/Board Member | 82 | 01-06-91 |
Joseph Goldstein
BRD | Director/Board Member | 83 | 01-06-91 |
George Sing
BRD | Director/Board Member | 74 | 08-01-88 |
Founder | 64 | 08-01-88 | |
Arthur Ryan
BRD | Director/Board Member | 81 | 01-01-03 |
N. Coles
BRD | Director/Board Member | 63 | 17-02-17 |
David Schenkein
BRD | Director/Board Member | 66 | 08-09-23 |
Bonnie Bassler
BRD | Director/Board Member | 61 | 12-09-16 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 10 | 1 818 146 | 0 | 0 | 77,74 % |
Aandeel B | 1 | 133 443 750 | 105 156 512 ( 78,80 %) | 25 500 000 ( 19,11 %) |
Bedrijfsgegevens
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
10591-6707, Tarrytown
+914 847 7000
http://www.regeneron.comBedrijven van de groep
Naam | Categorie en sector |
---|---|
Regeneron Ireland DAC
Regeneron Ireland DAC BiotechnologyHealth Technology Part of Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC is a leading Irish biotechnology company that uses science to develop new medicines for patients. The private company is located in Ireland. The company successfully manufactures a range of biopharmaceuticals for patients worldwide, including approved therapeutic proteins and those involved in clinical studies. |
Biotechnology
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,79% | 96,84 mld. | |
-3,30% | 102 mld. | |
-0,44% | 21,48 mld. | |
-18,35% | 20,82 mld. | |
-7,45% | 18,6 mld. | |
-40,31% | 16,81 mld. | |
-26,84% | 13,78 mld. | |
+0,59% | 13,4 mld. | |
+20,86% | 11,06 mld. | |
-21,69% | 8,88 mld. |
- Beurs
- Aandelen
- Koers REGN
- Onderneming Regeneron Pharmaceuticals, Inc.